Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¿ªÀü»ç ÁßÇÕ È¿¼Ò¿¬¼â ¹ÝÀÀÀ» ÀÌ¿ëÇÑ Àü¸³¼±¾Ï ȯÀÚÀÇ ¹Ì¼¼ÀüÀÌ ºÐ¼® Molecular Staging of Micrometastasis in Prostatic Cancer using RT-PCR

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 1È£ p.41 ~ 46
¼Ò¼Ó »ó¼¼Á¤º¸
±è¹ý¿Ï/Bup Wan Kim ±Ç¼øÈÍ/Àå¼¼±¹/Á¤¿îº¹/±èÁ¤¿Ï/Soon Weon Kwen/Sae Kook Chang/Yoon Bok Jung/Jung Wan Kim

Abstract

°á·Ð
Àü¸³¼±¾ÏÀÇ Á¶±âÁø´Ü°ú Ç÷Áß ¹Ì¼¼ÀüÀÌ Àü¸³¼±¾Ï ¼¼Æ÷¸¦ ¹ß°ßÇϱâ À§ÇÏ¿© ÀÓ»óÀû °Ë»ç¿¡¼­
ÀüÀÌ°¡ ÀÎÁ¤µÇ´Â ȯÀÚÁß Ä¡·áÀü ȯÀÚ±º(¥°±º, 13¸í), Ä¡·áÈÄ È¯ÀÚ±º(¥±±º, 16¸í)°ú ÀÓ»ó°Ë»ç
¿¡¼­ ÀüÀÌ°¡ °üÂûµÇÁö ¾ÊÀº ±º(¥²±º, 5¸í)À¸·Î ºÐ·ùÇÏ¿© Ç÷Çà³»ÀÇ ¹Ì¼¼ÀüÀÌ Àü¸³¼±¼¼Æ÷¸¦ °Ë
ÃâÇϱâ À§ÇÏ¿© PSA¿Í PSMAÀÇ cDNA¸¦ ´ë»óÀ¸·Î nested RT-PCR ½ÇÇèÀ» ½ÃÇàÇÏ¿´´Ù. ¥°
±ºÀÇ °æ¿ì 6¸í¿¡¼­ PSA, 13¸íÁß 10¸í¿¡¼­ PSMAÀÇ cDNA°¡ °ËÃâµÇ¾úÀ¸¸ç, ¥±±ºÀÇ °æ¿ì 16
·ÊÁß 8·Ê¿¡¼­ PSMAÀÇ cDNA°¡ °ËÃâµÇ¾úÀ¸³ª PSA´Â ´Ü 1·Ê°¡ °ËÃâµÇ¾ú´Ù. ±¹¼ÒÇü Àü¸³¼±
¾Ï ȯÀÚµéÀÇ °æ¿ì 1¸í¿¡¼­ PSMAÀÇ cDNA°¡ °ËÃâµÇ¾ú´Ù. ȯÀÚ ¼ö°¡ ºÎÁ·ÇÏ¿© Åë°èÀû ÀǹÌ
´Â ºÎ¿©ÇÒ ¼ö ¾øÀ¸³ª È£¸£¸ó¿ä¹ýÀÇ Àû¿ë ÈÄ Ç÷Áß PSAÀÇ °ËÃâÀº °¨¼ÒµÇ³ª »ó´ëÀûÀ¸·Î
PSMAÀÇ °ËÃâÀ²Àº ³ô¾Æ Ä¡·áÈ¿°ú ÆÇÁ¤ÀÇ ±âÁØÀ¸·Î ÀÌ¿ëÇÒ ¼ö ÀÖÀ¸¸®¶ó »ý°¢µÇ¸ç PSMA°¡
PSAº¸´Ù ´õ¿í ƯÀÌÀûÀÎÁö, ¹Î°¨µµ°¡ ³ôÀº °Ë»ç ¹æ¹ýÀÎÁö ÃßÈÄ Áö¼ÓÀûÀÎ ¿¬±¸°¡ ¿ä±¸µÈ´Ù
ÇÏ°Ú´Ù.

Purpose : Despite advances in the treatment of cancer, recurrence and metastasis
continue to pose major problems in clinical mamagement. Recently, molecular based
peripheral blood assay using the reverse transcriptase-polymerase chain
reaction(RT-PCR) has been shown to be highly sensitive molecular staging modality for
detecting extraprostatic disease pre-and postoperatively. The assay uses primers those
are specific for prostate specific antigen(PSA) and prostate specific membrane
antigen(PSMA).
Materials and Methods : We compared the application of RT-PCR assay for PSA
versus PSMA. These assays were applied to ribonucleic acids extracts from the
peripheral blood lymphocyte fraction of 29 patients with metastaic prostate cancer, in
which, 13 cases were non neoadjuvant hormonal therapy(NHT) group. In addition, blood
specimens from 5 clinically localized cancer were tested.
Results : Of 13 metastatic untreated patients 6 had positive for PSA, while 10 case
had positive results for PSMA. Among the 16 patients with hormone treated metastatic
cancer patients, 8(50%) had positive for PSMA while only 1 had positive for PSA. Of 5
localized prostatic cancer only 1 had positive result just for PSMA. In neoadjuvant
hormone treated group, marked reduction in incidence of positive RT-PCR for PSA was
noted. An additional explanation is that PSMA may be expressed in hormone refractory
cancer.
Conclusions : Presently RT-PCR assay using PSMA is highly sensitive and more
accurate than PSA RT-PCR for predicting micrometastasis. We are continuing to
increase our patient number and may increase our ability to detect early localized cancer
using a molecular approach.

Å°¿öµå

Prostatic cancer; PSA; Prostate specific membrane antigen; Micrometastasis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS